rs5744948
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS1
The NM_006231.4(POLE):āc.4730A>Cā(p.Glu1577Ala) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000917 in 1,613,520 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (ā ā ).
Frequency
Consequence
NM_006231.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLE | NM_006231.4 | c.4730A>C | p.Glu1577Ala | missense_variant, splice_region_variant | 37/49 | ENST00000320574.10 | NP_006222.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLE | ENST00000320574.10 | c.4730A>C | p.Glu1577Ala | missense_variant, splice_region_variant | 37/49 | 1 | NM_006231.4 | ENSP00000322570.5 |
Frequencies
GnomAD3 genomes AF: 0.000460 AC: 70AN: 152170Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000124 AC: 31AN: 250866Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135730
GnomAD4 exome AF: 0.0000534 AC: 78AN: 1461232Hom.: 0 Cov.: 34 AF XY: 0.0000399 AC XY: 29AN XY: 726836
GnomAD4 genome AF: 0.000460 AC: 70AN: 152288Hom.: 0 Cov.: 33 AF XY: 0.000376 AC XY: 28AN XY: 74458
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The POLE p.Glu1577Ala variant was identified in dbSNP (ID: rs5744948) and ClinVar (classified as benign by Quest Diagnostics Nichols Institute San Juan Capistrano, likely benign by Invitae and uncertain significance by GeneDx, Prevention Genetics and True Health Diagnostics), but was not identified in Cosmic. The variant was identified in control databases in 50 of 282236 chromosomes at a frequency of 0.0001772 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: African in 48 of 24740 chromosomes (freq: 0.00194) and Latino in 2 of 35388 chromosomes (freq: 0.000057), but was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Other, or South Asian populations. The p.Glu1577 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The p.Glu1577Ala variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. A functional study in yeast found no significant effect on DNA polymerase function or mutagenesis with the variant compared to wildtype (Daee_2010_PMID:19966286). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 16, 2020 | This variant is associated with the following publications: (PMID: 19966286, 20951805) - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | True Health Diagnostics | Apr 27, 2018 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 29, 2017 | - - |
POLE-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 30, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at